TABLE 2.

Relationship between patient clinical characteristics and treatment response

Characteristics	OR (95% CI)	p value
Age (<60 years vs. ≥60 years)	0.9 (0.4–1.9)	0.771
Sex (male vs. female)	0.7 (0.3–2.0)	0.543
ECOG performance status (0–1 vs. 2)	7.5 (3.0–18.9)	<0.001
Alcohol use (current or previous vs. never)	2.1 (1.0–4.6)	0.061
Lung metastasis (yes vs. no)	1.5 (0.7–3.1)	0.316
Lymph nodes metastasis (yes vs. no)	0.8 (0.4–1.8)	0.641
Bone metastasis (yes vs. no)	1.0 (0.3–3.9)	1.000
Peritoneum metastasis (yes vs. no)	1.0 (0.3–3.9)	1.000
Intra‐abdominal implantation (yes vs. no)	1.6 (0.3–8.5)	0.897
Adrenal gland metastasis (yes vs. no)	0.8 (0.2–3.8)	1.000
Child‐Pugh stage (A vs. B)	2.8 (1.0–8.1)	0.053
BCLC stage (B vs. C)	1.1 (0.3–4.1)	1.000
Alpha‐Fetoprotein (<400 IU/ml vs. ≥400 IU/ml)	0.7 (0.3–1.5)	0.332
Macrovascular invasion (yes vs. no)	0.8 (0.4–1.6)	0.498
Viral status (hepatitis B vs. uninfected)	1.4 (0.4–4.9)	0.836
Liver cirrhosis (yes vs. no)	1.7 (0.7–4.1)	0.282
Previous immunotherapy (yes vs. no)	2.0 (0.5–7.6)	0.506
Previous antiangiogenic therapy (yes vs. no)	1.7 (0.8–3.7)	0.190
Treatment systemic lines (0 vs. ≥1)	1.9 (0.9–4.1)	0.096
Previous surgery (yes vs. no)	0.9 (0.4–1.8)	0.694

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; OR, odds ratio; vs., versus.